平安好醫生(01833.HK)續挫12%創廿個月低 中期虧損擴大
中績虧損年增逾3倍平安好醫生(01833.HK)連跌第二天,今天股價再尋底,最低見52.35元,創廿個月低,現報52.66元,挫逾12%,成交844萬股。
平安好醫生日前公布,中期虧損擴大3.1倍至8.8億元人民幣(下同),每股虧損80分。期內,總收入按年升39%至38.18億元;毛利率按年降3.1個百分點至26.8%。若按非國際財務報告準則計算,公司中期經調整淨虧損按年擴大2.8倍至7.91億元。
首席財務官葉瀾績後表示,今明兩年是重要戰略投入期,期內對企業健康管理、互聯網醫院、線上藥店等領域將加大投資,但評估業務發展步伐後,維持公司於2024-2025年實現收支平衡預測不變,正有條不紊進行戰略投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.